CS
ADVM

Credit Suisse’s Adverum Biotechnologies ADVM Stock Holding History

Credit Suisse’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,208
Closed -$21K – 3580
2021
Q4 		$21K Sell
1,208
-5,939
-83% -$119K ﹤0.01% 4448
2021
Q3 		$154K Buy
7,147
+261
+4% +$6.66K ﹤0.01% 4276
2021
Q2 		$241K Buy
6,886
+40
+0.6% +$2.15K ﹤0.01% 4201
2021
Q1 		$675K Sell
6,846
-2,403
-26% -$289K ﹤0.01% 3569
2020
Q4 		$1M Sell
9,249
-6,995
-43% -$865K ﹤0.01% 3343
2020
Q3 		$1.67M Buy
16,244
+6,333
+64% +$948K ﹤0.01% 2553
2020
Q2 		$2.07M Buy
9,911
+4,799
+94% +$850K ﹤0.01% 2356
2020
Q1 		$500K Sell
5,112
-4,083
-44% -$476K ﹤0.01% 3113
2019
Q4 		$1.06M Buy
9,195
+7,975
+654% +$703K ﹤0.01% 3075
2019
Q3 		$66K Buy
1,220
+19
+2% +$2.14K ﹤0.01% 4010
2019
Q2 		$143K Sell
1,201
-45
-4% -$3.72K ﹤0.01% 3901
2019
Q1 		$65K Sell
1,246
-51
-4% -$2.06K ﹤0.01% 3886
2018
Q4 		$41K Buy
+1,297
New +$52.8K ﹤0.01% 3810
2018
Q3 		– Sell
-1,557
Closed -$82K – 3764
2018
Q2 		$82K Buy
+1,557
New +$93.6K ﹤0.01% 3856
2017
Q1 		– Sell
-1,198
Closed -$35K – 3789
2016
Q4 		$35K Sell
1,198
-267
-18% -$8.73K ﹤0.01% 4047
2016
Q3 		$60K Sell
1,465
-3,505
-71% -$133K ﹤0.01% 3998
2016
Q2 		$157K Buy
4,970
+3,920
+373% +$177K ﹤0.01% 3953
2016
Q1 		$54K Sell
1,050
-978
-48% -$54.6K ﹤0.01% 3881
2015
Q4 		$193K Buy
2,028
+603
+42% +$53K ﹤0.01% 3905
2015
Q3 		$117K Sell
1,425
-2,496
-64% -$319K ﹤0.01% 4078
2015
Q2 		$637K Buy
3,921
+1,692
+76% +$571K ﹤0.01% 3540
2015
Q1 		$904K Buy
2,229
+203
+10% +$85.8K ﹤0.01% 3057
2014
Q4 		$1.09M Buy
+2,026
New +$781K ﹤0.01% 3061

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Credit Suisse's ADVM Position: Q1 2022 in Review

Credit Suisse sold out of Adverum Biotechnologies (ADVM) in Q1 2022, closing a stake of 1,208 shares — an estimated $21K sold.

Credit Suisse first reported a position in ADVM in Q4 2014 and held it in 23 quarters. The position peaked at $2.07M in Q2 2020. 92 funds tracked by Wall St. Rank hold ADVM as of Q1 2022.

  • Credit Suisse reported no remaining Adverum Biotechnologies position as of Q1 2022 after selling out during the quarter.
  • Credit Suisse sold 1,208 Adverum Biotechnologies shares in Q1 2022, an estimated $21K.
  • Credit Suisse first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 23 quarters.
  • Credit Suisse's Adverum Biotechnologies position peaked at $2.07M in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2022.

Based on Credit Suisse's 13F filing for Q1 2022, filed 16 May 2022.